AstraZeneca hires former GSK head as CFO
pharmafile | November 1, 2013 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | AstraZeneca, GSK, dunoyer
AstraZeneca has confirmed that Marc Dunoyer has been appointed chief financial officer and will join the company’s Board as an executive director.
He succeeds Simon Lowth who leaves AstraZeneca as previously announced. Dunoyer begins work today and will report to the firm’s chief executive Pascal Soriot and remain a member of the senior executive team.
Dunoyer who was the executive VP, Global Portfolio & Product Strategy, joined AstraZeneca from GlaxoSmithKline in June 2013. He qualified as an accountant and his subsequent career in pharmaceuticals has given him extensive experience of the industry including finance and accounting; corporate strategy and planning; research and development; sales and marketing; business reorganisation; and business development.
Soriot said: “I’m delighted with Marc’s appointment as CFO. Following a thorough and extensive search it became clear that Marc possessed the rare blend of financial, business and science experience that will be critical in this role in the coming years as we focus on returning AstraZeneca to growth and achieving scientific leadership.”
Leif Johansson, chairman of the firm’s Board added: “Marc’s unique combination of global industry knowledge gained in emerging and established markets and strong business and financial experience will enable him to make a significant contribution to the success of the company at senior executive and Board level.”
Related Content
GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis
GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and …
NICE recommends Benralizumab for Rare Form of Vasculitis
The National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s benralizumab (Fasenra) as …
NICE approves AstraZeneca’s dual immunotherapy for advanced liver cancer
AstraZeneca has received a positive recommendation from the National Institute for Health and Care Excellence …
